OKYO PHARMA LTD

OKYO stock represents shares of OKYO Pharma Limited, a clinical-stage biopharmaceutical company. The company focuses on developing therapies for inflammatory eye diseases and chronic pain. As a small-cap biotech, OKYO's stock is often driven by clinical trial updates and regulatory news rather than commercial product sales. Investors can find the latest details on the stock's quote page.

OKYO Pharma Limited's shares are listed on the Nasdaq Capital Market under the ticker symbol OKYO. The company is incorporated in Guernsey, but its U.S. listing allows investors to trade shares during standard U.S. market hours. For the most current listing details and exchange information, refer to the OKYO stock page.

Recent performance for OKYO depends on clinical trial developments, financing activities, and broader biotech market sentiment. As a small-cap stock, OKYO can experience significant price swings. For the latest price changes and performance data, please check the current OKYO stock page, which displays up-to-date figures and charts.

OKYO is a small-cap biotech stock, so its trading volume can vary considerably. Liquidity may be lower than larger, more established companies, which can lead to wider bid-ask spreads and increased volatility. Investors should review current volume and market depth on the OKYO stock page before placing trades.

Key risks include clinical trial failures, regulatory delays, and the need for additional capital to fund research. As a clinical-stage company, OKYO may not achieve profitability soon, and its stock price can be highly volatile. Competition, intellectual property challenges, and general market conditions also pose risks. Review OKYO's SEC filings for detailed risk factors.

Analyzing OKYO involves reviewing its financial statements, particularly cash burn rate, research and development expenses, and available cash reserves. Since OKYO is clinical-stage, revenue may be minimal or absent. Key metrics include operating expenses, net loss, and financing activities. These figures are available in OKYO's quarterly and annual reports filed with the SEC.